Xeris Biopharma Holdings (XERS) Total Liabilities (2020 - 2026)

Xeris Biopharma Holdings' Total Liabilities history runs 7 years deep, the most recent figure standing at $379.0 million for Q1 2026.

• Quarterly Total Liabilities rose 8.11% year-over-year to $379.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $379.0 million (up 8.11% YoY) and the FY2025 annual result came in at $369.8 million, up 4.87% from the prior year.
• Total Liabilities was $379.0 million for Q1 2026 at Xeris Biopharma Holdings, up from $369.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $379.0 million in Q1 2026 and bottomed at $241.2 million in Q1 2022.
• A 5-year average of $324.5 million and a median of $345.8 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 85.44% — and 2025, when it advanced 0.85%.
• Xeris Biopharma Holdings' Total Liabilities stood at $299.3 million in 2022, then advanced by 10.04% to $329.4 million in 2023, then rose by 7.07% to $352.7 million in 2024, then rose by 4.87% to $369.8 million in 2025, then rose by 2.48% to $379.0 million in 2026.
• Business Quant data shows XERS's Total Liabilities at $379.0 million in Q1 2026, $369.8 million in Q4 2025, and $371.1 million in Q3 2025.